BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31397438)

  • 1. [Somatic Mutations Associated with Metastasis in Acral Melanoma].
    Abramov IS; Emelyanova MA; Ryabaya OO; Krasnov GS; Zasedatelev AS; Nasedkina TV
    Mol Biol (Mosk); 2019; 53(4):648-653. PubMed ID: 31397438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences.
    Dai B; Cai X; Kong YY; Yang F; Shen XX; Wang LW; Kong JC
    Hum Pathol; 2013 Aug; 44(8):1472-8. PubMed ID: 23528861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.
    Sharma G; Lian CG; Lin WM; Amin-Mansour A; Jané-Valbuena J; Garraway L; Bao W; Yoon CH; Ibrahim N
    J Cutan Pathol; 2016 Oct; 43(10):884-91. PubMed ID: 27251777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.
    Moon KR; Choi YD; Kim JM; Jin S; Shin MH; Shim HJ; Lee JB; Yun SJ
    J Invest Dermatol; 2018 Apr; 138(4):933-945. PubMed ID: 29191620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma.
    Ekedahl H; Lauss M; Olsson H; Griewank KG; Schadendorf D; Ingvar C; Jönsson G
    Pigment Cell Melanoma Res; 2016 Sep; 29(5):598-600. PubMed ID: 27301352
    [No Abstract]   [Full Text] [Related]  

  • 8. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
    Ashida A; Takata M; Murata H; Kido K; Saida T
    Int J Cancer; 2009 Feb; 124(4):862-8. PubMed ID: 19035443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
    Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.
    Niu HT; Zhou QM; Wang F; Shao Q; Guan YX; Wen XZ; Chen LZ; Feng QS; Li W; Zeng YX; Zhang XS
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):646-53. PubMed ID: 23751074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
    Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
    Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
    Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
    J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis.
    Furney SJ; Turajlic S; Stamp G; Thomas JM; Hayes A; Strauss D; Gavrielides M; Xing W; Gore M; Larkin J; Marais R
    Pigment Cell Melanoma Res; 2014 Sep; 27(5):835-8. PubMed ID: 24913711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acral melanoma: correlating the clinical presentation to the mutational status.
    Ravaioli GM; Dika E; Lambertini M; Chessa MA; Fanti PA; Patrizi A
    G Ital Dermatol Venereol; 2019 Oct; 154(5):567-572. PubMed ID: 29512974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutation is uncommon in acral lentiginous melanoma.
    Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
    J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.